First African country introduces GSK's pneumococcal vaccine

GlaxoSmithKlineGlaxoSmithKline (GSK) announced the incorporation of its pneumococcal vaccine into the Kenyan national immunisation programme. Kenya is the first African country to receive pneumococcal vaccines through the innovative financing mechanism known as the Advance Market Commitment (AMC), which is designed to bring heavily discounted vaccines to children living in the world's poorest countries.

At a commemoration ceremony to be held in the capital city of Nairobi on 14 February, government officials will be joined by representatives of the Global Alliance for Vaccines and Immunisation (GAVI), the Bill & Melinda Gates Foundation, UNICEF and GSK, to launch the programme. Consequently, millions of children will be vaccinated and protected against pneumococcal disease, which is the world's leading killer of children under five years of age.

GSK’s Synflorix™ is the first vaccine to be rolled out in Africa under the AMC framework and provides protection against 10 strains of the pneumococcus bacteria that are responsible for the large majority of pneumococcal disease in Kenya and worldwide. Sierra Leone is also introducing pneumococcal vaccines through the AMC in Africa, and Yemen is doing the same in the Middle East. Certain countries in Latin America are also eligible to receive pneumococcal vaccines through the AMC. Nicaragua began vaccinating children in late 2010 and Guyana is introducing vaccines this year. In total, GAVI anticipates that more than 40 developing countries will receive pneumococcal vaccines through the AMC by 2015.

The AMC accelerates access to new and innovative vaccines. By guaranteeing the availability of initial purchase funds, the AMC enables vaccine makers to invest in development and manufacturing capability. In addition, by contracting significant volumes over the long-term, manufacturers can significantly reduce the cost of their vaccines.

Jean Stéphenne, Chairman and President of GlaxoSmithKline Biologicals said: "The architects of the AMC have delivered on their promise to accelerate access to vaccines for children living in the world's poorest countries. Their vision, Kenya's leadership and the willingness of donors to realise this commitment have resulted in a genuine breakthrough to global public health."

The AMC is backed by five donor countries - the United Kingdom, Canada, Russia, Norway and Italy - and the Bill & Melinda Gates Foundation. In March 2010,GSK and Pfizer signed 10-year contracts through the AMC to provide up to 300 million doses each of their pneumococcal vaccines, at an approximate reduction of 90% of the cost in developed markets. GSK has invested more than US$400 million in a plant to manufacture Synflorix in Singapore to meet expected global demand.

Kenya began administering immunisations in early January with Synflorix, which is supplied in a two-dose presentation to help developing countries optimise their storage and transport space. Kenya rolled out a comprehensive training programme to prepare its healthcare workers and clinics to administer the vaccine alongside the traditional immunisations Kenyan children already receive.

About Synflorix™

  • Synflorixhelps protect against diseases due to pneumococcus bacteria. It contains 10 serotypes, three of which - 1, 5, and 14 - were required to be included in the vaccine for the AMC due to the high burden of invasive diseases caused by these serotypes in the developing world.(1)
  • It is the most technically sophisticated of GSK's vaccines and each dose takes a year to make. It is essentially ten vaccines in one. Each individual strain is grown and developed separately - it is only at the very end of the process that they are brought together as one vaccine.
  • Over the next decade, GSK has committed to provide an average of up to 30 million doses annually under the AMC.
  • GSK has invested more than US$400 million in a dedicated manufacturing plant in Singapore that will produce several hundred million doses of the vaccine annually in the coming years.
  • Synflorix was the first pneumococcal vaccine to receive World Health Organisation (WHO) 'prequalification' for global use, a regulatory endorsement that is a precondition for participation in the AMC.

About pneumococcal disease

  • Pneumococcal disease is a global health issue. Each year, S.pneumoniae infections are estimated to kill one million children under five years of age, mostly in developing countries.(2-3)
  • Pneumococcal bacteria can cause life-threatening diseases such as meningitis, pneumonia and bacteraemia.(4)
  • S.pneumoniae can also cause less severe, but considerably more common diseases of the respiratory tract such as middle ear infections, sinusitis and bronchitis.(4)

About GlaxoSmithKline
GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer.

1. Pneumococcal Regional Serotype Distribution for Pneumococcal AMC TPP, PneumoADIP Report, November 2008. Last accessed February 2011.
2. GAVI Alliance 2007. The Pneumococcal AMC: Ready to save lives. Last accessed February 2011.
3. World Health Organization. Immunization,Vaccines and Biologicals. Last accessed February 2011
4. World Health Organization. Weekly epidemiological record. Last accessed February 2011.

Most Popular Now

BioNTech's statement on patent infringement lawsui…

BioNTech SE (Nasdaq: BNTX, "BioNTech") published an official statment: "BioNTech is aware of reports that Moderna has sued Pfizer and BioNTech, alleging that COMIRNATY® i...

Xenpozyme™ (olipudase alfa-rpcp) approved by FDA a…

The U.S. Food and Drug Administration (FDA) has approved Xenpozyme™ (olipudase alfa-rpcp) for the treatment of non-central nervous system (non-CNS) manifestations of acid...

FDA grants Breakthrough Therapy Designation to Pfi…

Pfizer Inc. (NYSE:PFE) today announced that its investigational Group B Streptococcus (GBS) vaccine candidate, GBS6 or PF-06760805, received Breakthrough Therapy Designat...

Malaria booster vaccine shows durable high efficac…

Researchers from the University of Oxford and their partners have today reported new findings from their Phase 2b trial following the administration of a booster dose of ...

Research reveals widespread use of ineffective COV…

Monoclonal antibodies are laboratory-designed treatments tailor-made to fight specific infections. In early 2021, the U.S. Food & Drug Administration issued emergency use...

Efficacy, cash and more will increase booster shot…

The more effective the COVID-19 booster, the more likely people are to get it, according to new Cornell research. And they are more likely to accept the booster shot with...

Strict COVID lockdowns in France improved cardiova…

A new paper in European Heart Journal - Digital Health, published by Oxford University Press, indicates that social-distancing measures like total lockdown have a measura...

U.S. clinical trial evaluating antiviral for monke…

A Phase 3 clinical trial evaluating the antiviral tecovirimat, also known as TPOXX, is now enrolling adults and children with monkeypox infection in the United States. St...

Stem cell-gene therapy shows promise in ALS safety…

Cedars-Sinai investigators have developed an investigational therapy using support cells and a protective protein that can be delivered past the blood-brain barrier. This...

Novartis invests in early technical development ca…

Novartis today announced it is investing in next-generation biotherapeutics with the creation of a fully integrated, dedicated USD 300m scientific environment that will b...

Drug turns cancer gene into "eat me" fla…

Tumor cells are notoriously good at evading the human immune system; they put up physical walls, wear disguises and handcuff the immune system with molecular tricks. Now...

Mucosal antibodies in the airways protect against …

High levels of mucosal antibodies in the airways reduce the risk of being infected by omicron, but many do not receive detectable antibodies in the airways despite three ...